The stock has a 36-month beta value of 1.18. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ARQT is 97.27M, and at present, short sellers hold a 20.21% of that float. On May 07, 2024, the average trading volume of ARQT was 3.85M shares.
ARQT) stock’s latest price update
The stock of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has decreased by -0.63 when compared to last closing price of 8.00.Despite this, the company has seen a loss of -9.45% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-29 that WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. financial markets close.
ARQT’s Market Performance
Arcutis Biotherapeutics Inc (ARQT) has seen a -9.45% fall in stock performance for the week, with a -29.89% decline in the past month and a 32.06% surge in the past quarter. The volatility ratio for the week is 10.03%, and the volatility levels for the past 30 days are at 8.45% for ARQT. The simple moving average for the last 20 days is -18.24% for ARQT’s stock, with a simple moving average of 23.11% for the last 200 days.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with Mizuho repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to Mizuho is $8 based on the research report published on January 03, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $4, previously predicting the price at $57. The rating they have provided for ARQT stocks is “Neutral” according to the report published on October 26th, 2023.
Goldman gave a rating of “Neutral” to ARQT, setting the target price at $6 in the report published on October 13th of the previous year.
ARQT Trading at -20.98% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.73% of loss for the given period.
Volatility was left at 8.45%, however, over the last 30 days, the volatility rate increased by 10.03%, as shares sank -36.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.87% lower at present.
During the last 5 trading sessions, ARQT fell by -9.45%, which changed the moving average for the period of 200-days by -23.26% in comparison to the 20-day moving average, which settled at $9.49. In addition, Arcutis Biotherapeutics Inc saw 146.13% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Watanabe Todd Franklin, who sale 13,783 shares at the price of $8.74 back on May 02 ’24. After this action, Watanabe Todd Franklin now owns 860,750 shares of Arcutis Biotherapeutics Inc, valued at $120,433 using the latest closing price.
Burnett Patrick, the of Arcutis Biotherapeutics Inc, sale 9,555 shares at $8.74 during a trade that took place back on May 02 ’24, which means that Burnett Patrick is holding 259,745 shares at $83,490 based on the most recent closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -4.04 for the present operating margin
- 0.91 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -4.39. The total capital return value is set at -0.82.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -1.22. The debt to equity ratio resting at 2.28. The interest coverage ratio of the stock is -8.11.
Currently, EBITDA for the company is -239.22 million with net debt to EBITDA at -0.5. When we switch over and look at the enterprise to sales, we see a ratio of 17.29. The receivables turnover for the company is 2.31for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.08.
Conclusion
To sum up, Arcutis Biotherapeutics Inc (ARQT) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
